CoChat

The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology

Open access
Rouvinov, Keren, Naamneh, Rashad, Yakobson, Alexander, Najjar, Wenad, Abu Amna, Mahmoud, Soklakova, Arina, Abu Zeid, Ez El Din, Brenner, Ronen, Asla, Mohnnad, Ghalion, Fahmi Abu, Abu Juma’a, Ali, Meirovitz, Amichay, Shalata, Walid · 2026 · Diagnostics

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Background: Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), represents a significant advancement in oncology. Unlike traditional tissue biopsies, ctDNA offers a minimally invasive, real-time approach to cancer management. It has demonstrated considerable potential in early cancer detection, monitoring of therapeutic responses, and assessing minimal residual disease (MRD) to predict recurrence. By enabling comprehensive molecular profiling through a simple blood test, ctDNA supports the core principles of precision oncology, facilitating more personalized and adaptive treatment strategies. Methods: In the following article we describe the recent developments focused on refining ctDNA detection assays to improve sensitivity and specificity. Advanced technologies, including next-generation sequencing (NGS) and digital PCR, are commonly employed. The integration of artificial intelligence (AI) and multi-omics approaches—such as combining genomic, epigenomic, and transcriptomic data—has further enhanced the analytical power of ctDNA assays. Results: Emerging evidence shows that ctDNA-based liquid biopsy enables dynamic, real-time tracking of tumor evolution and therapeutic resistance. Clinical studies have demonstrated its efficacy in detecting early-stage cancers, guiding treatment selection, and predicting relapse with higher accuracy than some conventional methods. Moreover, AI-enhanced algorithms have improved signal detection, allowing for more precise and earlier identification of actionable mutations and MRD. Conclusions: ctDNA analysis via liquid biopsy is poised to revolutionize cancer care by offering a non-invasive, precise, and adaptive tool for tumor characterization and monitoring. Although obstacles remain—particularly regarding assay sensitivity, standardization, and economic feasibility—ongoing technological innovations and multi-omics integration are rapidly advancing its clinical viability. With continued progress, ctDNA-based liquid biopsy is likely to become a cornerstone of routine oncology practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics16040523

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The figure illustrates the process and the main biomarkers detectable in a blood sample.
Figure 1 The figure illustrates the process and the main biomarkers detectable in a blood sample.CC BY · PubMed Central
Figure 2 Comparison between ctDNA and cfDNA.
Figure 2 Comparison between ctDNA and cfDNA.CC BY · PubMed Central
Figure 3 Flow diagram of the literature search.
Figure 3 Flow diagram of the literature search.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Chaudhry, S.E., and Zarmina, E. (2025). Liquid Biopsy: Techniques, Biomarker Insights, and Oncological Impact, Springer.

Cited by

See all 19

Metadata

Authors
Rouvinov, K., Naamneh, R., Yakobson, A., Najjar, W., Abu Amna, M., Soklakova, A., Abu Zeid, E. E. D., Brenner, R., Asla, M., Ghalion, F. A., Abu Juma’a, A., Meirovitz, A., & Shalata, W.
Affiliations
  • Ben-Gurion University of the Negev (IL)
  • Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel
  • Hadassah Medical Center (IL)
  • Department of Oncology, The Emek Medical Centre, Afula 18341, Israel
  • Wolfson Medical Center (IL)
Corresponding author
Shalata, Walid
Venue
Diagnostics
Publisher
MDPI AG
Published
2026-02-09
Volume
16
Issue
4
Pages
523
ISSN
2075-4418 (ISSN-L)
OpenAlex
W7128422134
Cited by
14
References
44
Citations by year
2026: 14
FWCI
11.79
Type
journal article
Language
en
Open access
Locations
  • Diagnostics (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
liquid biopsy, circulating tumor DNA, early cancer detection, minimal residual disease, treatment response monitoring, precision oncology, digital PCR, next-generation sequencing, multi-omics integration, treatment resistance, tumor recurrence prediction, actionable mutations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology. https://app.cochat.ai/papers/10.3390/diagnostics16040523
The paper
Rouvinov, K., Naamneh, R., Yakobson, A., Najjar, W., Abu Amna, M., Soklakova, A., Abu Zeid, E. E. D., Brenner, R., Asla, M., Ghalion, F. A., Abu Juma’a, A., Meirovitz, A., & Shalata, W. (2026). The Transformative Potential of Liquid Biopsies and Circulating Tumor DNA (ctDNA) in Modern Oncology. Diagnostics. https://doi.org/10.3390/diagnostics16040523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.